Fractyl Health, INC Form 4 insider transactions

Director Samuel Conaway of Fractyl Health, Inc. (GUTS) purchased 8,550 shares of common stock at a weighted average price of $1.1654 on March 13, 2025.

Chief Scientific Officer Timothy Kieffer reports the acquisition of stock options in FRACTYL HEALTH, INC.

Sarah Toomey, General Counsel of FRACTYL HEALTH, INC., reports the acquisition of stock options, including those related to performance criteria met after the company's IPO.

Lisa Davidson, CFO of Fractyl Health, reports the acquisition of stock options.

Jay David Caplan, President and Chief Product Officer of FRACTYL HEALTH, INC., reports acquisition of stock options.

CEO of Fractyl Health, Harith Rajagopalan, reports the acquisition of stock options, including those tied to performance criteria, as disclosed in a recent SEC Form 4 filing.

CEO Harith Rajagopalan exercised stock options and sold shares of Fractyl Health, Inc. on January 30 and 31, 2025, according to a Form 4 filing with the SEC.

Jay David Caplan, President and Chief Product Officer of Fractyl Health, executed multiple stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Fractyl Health's CEO, Harith Rajagopalan, exercised stock options and sold shares to cover tax obligations.

Jay David Caplan, President and Chief Product Officer of Fractyl Health, Inc., reported the acquisition and sale of company shares following the vesting of restricted stock units.

Jay David Caplan, President and Chief Product Officer of FRACTYL HEALTH, INC., reported the sale of 65,000 shares of common stock on September 12, 2024, while also exercising options to acquire 95,484 shares.

Adrian Kimber, Chief Commercial Officer of Fractyl Health, Inc., acquired 250,000 stock options on April 1, 2024.